Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial Guang-Yi Sun, MDa,* ∙ Si-Ye Chen, MDa,* ∙ Yu Tang, MDa,* ∙ Hui Fang, MDa ∙ Yong-Wen Song, MDa ∙ Yue-Ping Liu, MDa ∙ et al.

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial Guang-Yi Sun, MDa,* ∙ Si-Ye Chen, MDa,* ∙ Yu Tang, MDa,* ∙ Hui Fang, MDa ∙ Yong-Wen Song, MDa ∙ Yue-Ping Liu, MDa ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00297-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_astro26&_hsenc=p2ANqtz-9vq7hSfc3UWPp2HQsy5d_Yfm_qd_9YtG447MNplSTAPzJyjc-GK8j7MS07qzZmcFUveER0C5q0aMWJp-tYgifg86bblA&_hsmi=442821435&utm_source=hs_email Hypofractionated radiotherapy is an established alternative to conventional fractionation for breast cancer, but long-term evidence after mastectomy with regional nodal irradiation is scarce. We aimed to assess the long-term efficacy and adverse event profile of hypofractionated versus conventional fractionated postmastectomy radiotherapy in high-risk breast cancer.